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ABSTRACT (274/274) 
 
Whereas early allograft dysfunction (EAD) negatively impacts on survival from the first 
months following liver transplantation (LT), direct-acting antivirals (DAAs) have 
revolutionized HCV therapy. In HCV-positive recipients, we investigated the EAD definition 
best predicting 90-day graft loss and identified EAD risk factors.  
From 11-2002 to 06-2016, 603 HCV-positive patients (hepatocellular carcinoma 53%) 
underwent a first LT with HCV-negative donors. Median recipient MELD score 15, median 
donor age 63 years. At LT, 77 (12.8%) patients were HCV RNA negative; negativization 
was achieved and maintained by pre-LT antiviral therapy (61 patients) or pre-
LT+preemptive post-LT course (16 patients); 60 (78%) patients received DAAs and 17 
(22%) interferon. We compared three different EAD definitions: a) bilirubin≥10 mg/dL or 
INR≥1.6 on day 7 post-LT or AST or ALT>2000 IU/L within 7 days of LT; b) bilirubin>10 
mg/dL on days 2 to 7 post-LT; c) MELD≥19 on day 5 post-LT.  
EAD defined by MELD≥19 on day 5 post-LT had the lowest negative (0.1) and the highest 
positive (1.9) likelihood ratio to predict 90-day graft loss. At 90 days post-LT, 9.2% of 
recipients with EAD lost their graft as opposed to 0.7% of those without EAD (p<0.001). At 
multivariate analysis considering variables available at LT, MELD at LT>25 (OR=7.4) or 
15-25 (OR=3.24), graft macrovesicular steatosis≥30% (OR=6.7), HCV RNA positive at LT 
(OR=2.7), donor age>70 years (OR=2.0), earlier LT era (OR=1.8), cold ischemia time≥8 
hours (OR=1.8) were significant risk factors for EAD.  
Conclusions. In HCV-positive patients, MELD≥19 on day 5 post-LT best predicts 90-day 
graft loss. Preventing graft infection by pre/peri-LT antiviral therapy reduces EAD 
incidence. This could prove to be most beneficial in high MELD patients and recipients of 
suboptimal grafts. 
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INTRODUCTION  
Hepatitis C virus (HCV) is the main cause of cirrhosis and hepatocellular carcinoma (HCC) 
and still represents the most common indication for liver transplantation (LT) in Europe and 
United States (1). Although infection recurs almost universally in patients who are viremic 
at the time of LT (2), the recent advent of safe and effective direct-acting antiviral agents 
(DAAs) has revolutionized HCV therapy. Yet, the debate about the best time to treat the 
infection in the transplant setting is still open (3-5). On one hand, pre-LT eradication is 
aimed at improving liver disease which may lead to the delisting of some patients (an 
appropriate strategy in the ongoing context of organ shortage) (6), and at preventing graft 
infection thus facilitating post-LT management (7). This approach could be particularly 
appropriate in areas where, in the last decade, median donor age has come to exceed 60 
years, thus leading to a more severe HCV recurrence (8). On the other hand, 
unpredictable waiting time, antiviral therapy duration, risk of patient death and/or tumour 
progression on the list, and higher rates of sustained virological response in transplant 
recipients compared with decompensated cirrhotic patients, incline clinicians to treat  
infection after LT, generally starting after three months from LT, as suggested in the last 
update of the European Association for the Study of the Liver recommendations (3). It is 
unlikely that clinical trials will be feasible to prospectively compare these two different 
approaches, as they would have to recruit a prohibitively large number of patients and 
extend over an exceedingly long time (5). 
In the last two decades the transplant community has increased its efforts to expand the 
donor pool by using so-called ‘extended criteria donors’ in order to circumvent donor organ 
shortage. A consequence of this policy has been an increased incidence of poor graft 
function immediately after transplant (9). Early allograft dysfunction (EAD) in LT recipients 
adversely affects graft and patient survival, starting from the very first months after LT, and 
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may lead to extrahepatic organ dysfunction, especially kidney impairment (10). Multiple 
definitions of EAD have been proposed in order to identify LT recipients who are at risk for 
graft loss within 90-180 days of transplant, such as: i) Olthoff’s definition: total bilirubin 
level ≥10 mg/dL or INR ≥1.6 on postoperative day 7 or AST or ALT level >2000 IU/L within 
the first 7 days (11); ii) Deschênes’s definition: peak total bilirubin level >10 mg/dL on 
postoperative days 2 to 7 (12); iii) Wagener’s definition: Model for End-stage Liver Disease 
(MELD) score on postoperative day 5 higher than 18.9 (13). 
Donor age >45 years, recipient MELD score at LT, donor body mass index, degree of graft 
macrovesicular steatosis, cold ischemia time and HCV infection have been reported as 
significant risk factors for EAD (11,14,15), but until now no study has either focused solely 
on the HCV-positive population, or, more relevantly, has investigated the potential impact 
of HCV RNA status at transplant on EAD incidence. 
This retrospective single-center study was performed on a series of HCV-positive first LT 
recipients, with the following objectives: i) to establish the EAD definition best predicting 
graft loss within 90 days of transplant; ii) to assess EAD impact on 90-day graft and patient 
survival; iii) to identify independent risk factors for EAD in this population.  
We intended herewith to generate new data which could be applied to optimize early 
outcomes of HCV-positive LT recipients in the current era of extraordinarily effective DAAs 
but of persisting organ shortage.  
 
MATERIALS AND METHODS 
Study population 
From November 2002 to June 2016, 1,706 first LTs were performed at the Liver 
Transplant Center of Turin, Italy. In this study, we enrolled 603 consecutive adult HCV-
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positive cirrhotic patients who underwent a first LT with grafts from HCV-negative, brain 
dead heart-beating donors. All livers were preserved with conventional static cold storage. 
Informed consent was signed by all patients upon entering the waiting list. Due to the 
retrospective design, no specific approval was sought from the Local Institutional Ethics 
Committee. By Italian law, Regional Transplantation Centers are the custodians of 
donor/recipient biomedical data also for research purposes. All study procedures complied 
with the ethical standards of the 2000 Declaration of Helsinki and the Declaration of 
Istanbul 2008. 
 
Data collection 
Variables collected in the study population and in their donors are shown in Table 1. 
The pattern and degree of fatty infiltration of the graft were assessed on liver biopsies 
which were routinely obtained at the time of transplant surgery, before closing the 
abdomen. 
Total bilirubin, INR, AST, ALT, serum creatinine were analyzed at LT and daily after 
surgery, up to day 7. 
Laboratory MELD was calculated at LT and on post-transplant day 5. 
Mortality or re-transplantation within 90 days were recorded and survival data were 
collected up to 31st December 2016. 
 
HCV testing 
Antibodies to HCV were detected by the Architect assay (Abbott Laboratories, Abbott Park, 
IL). HCV RNA was detected until April 2007 by signal amplification Branched-DNA test 
(Versant® HCV version 3.0, Bayer Diagnostic Corporation, Tarrytown, NY, US, range of 
quantitation 615-7.7 x 106 IU/mL); after April 2007 by the automated high-sensitivity system 
COBAS AmpliPrep®/COBAS TaqMan® HCV Version 1 (Roche Molecular Systems Inc, 
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range of quantitation 43-6.9 x 107 IU/mL); after October 2012, by the Version 2 of the 
AmpliPrep®/COBAS TaqMan® HCV test (range of quantitation 15-1 x 108 IU/mL). 
 
Clinical protocol 
Immunosuppression was based on calcineurin inhibitors (cyclosporine or tacrolimus), 
antimetabolites and steroids (tapered to suspension in 6 months). Moderate/severe acute 
rejection episodes were treated with high-dose methylprednisolone boluses on three 
consecutive days; monoclonal anti-CD3 antibodies were used in steroid-resistant 
rejections. 
Anti-HCV therapy before LT was based until May 2014 on ribavirin and peginterferon-α ± 
first generation protease inhibitors and it was applicable only in few well compensated 
cirrhotic patients affected by HCC. Since June 2014, DAAs plus ribavirin were used in all 
patients listed for LT with a MELD score below 25, a creatinine clearance ≥30 mL/min and 
an expected time on the waiting list of at least 3 months. Patients who received DAAs 
before LT and were HCV RNA negative for less than 30 days at the time of LT, continued 
antiviral therapy immediately after LT for at least 12 weeks, in order to consolidate HCV 
RNA negativization (16,17). 
 
Study outcome measure 
Graft loss within 90 days of transplant, defined as mortality or re-transplantation, was the 
study outcome measure. 
 
Study endpoint and objectives 
EAD was the study endpoint and it was investigated with three objectives: 
I) to establish the EAD definition best predicting graft loss within 90 days of transplant.    
For this purpose, we compared three previously published EAD definitions: a) total bilirubin 
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≥10 mg/dL or INR ≥1.6 on postoperative day 7 or AST or ALT >2000 IU/L within the first 
seven days (11); b) peak total bilirubin >10 mg/dL on postoperative days 2 to 7 (12); c) 
MELD score >18.9 on postoperative day 5 (13); 
II) to assess the extent of EAD impact on 90-day graft and patient survival; 
III) to identify EAD independent risk factors. 
 
Statistical analysis 
Categorical variables were reported as number (%) and quantitative variables were shown 
as median (25th - 75th percentiles). 
Receiver operating characteristic curve was plotted and the point on the curve closest to 
the upper left corner was considered the best cut-off value of MELD score on post-
transplant day 5 best predicting 90-day graft loss.  
Positive and negative likelihood ratios were calculated for each EAD definition. 
Kaplan-Meier analysis was performed to evaluate the effect of EAD on graft survival, and 
survival curves were compared using the log-rank test. 
Univariate analyses were carried out using chi-square test for categorical variables and 
Mann-Whitney test for continuous variables. 
To obtain a parsimonious set of EAD predictors, recipient and donor variables available at 
LT were selected based on the background knowledge. The variables were fitted into a 
logistic regression model and a stepwise backward elimination was used. Odds ratio (OR) 
and 95% confidence interval (CI) were reported. 
Data elaboration was performed using R software (version 3.3.1). 
 
RESULTS 
Of the 603 enrolled patients, a majority were males (81%), 10.2% were affected by HCV 
genotype 1a, 62.2% 1b, 7.4% 2, 13.9% 3 and 6.3% 4. They were affected by HCC in 
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53.4% of cases and their median MELD score at LT was 15. Seventy-seven patients 
(9.5% HCV genotype 1a; 56.8% 1b, 5.4% 2, 21.6% 3 and 6.7% 4) were HCV RNA 
negative at LT: 17 (22.1%) received peginterferon-α and ribavirin and 60 (77.9%) received 
DAAs plus ribavirin before LT. Sixteen patients bridged DAAs from pre- to post-LT for at 
least 12 weeks to maintain HCV RNA negativization. Two patients relapsed at week 4 after 
LT: the first one affected by HCV genotype 1b, was treated until LT with peginterferon-α 
plus ribavirin for 24 weeks and the second one affected by genotype 4, received 
sofosbuvir plus ribavirin for 141 days before LT; both patients were HCV RNA negative at 
LT by at least 30 days and stopped antiviral therapy at LT. The median donor age was 63 
years with one third of the donors being older than 70. The median donor risk index was 
1.83 and 3% of the grafts showed a macrovesicular steatosis ≥30% (Table 1). Table S1 
shows the clinical and demographic characteristics of donors and recipients according to 
HCC diagnosis.  
Fig. S1 depicts the trend of bilirubin, INR and creatinine during the first 7 days after LT. 
The rate of primary non function was 1% (6/603). Two patients lost their graft on day 1, 
two on day 4, one on day 5 and one on day 7 after surgery. They all underwent re-LT. 
According to the receiver operating characteristic curve, the best cut-off of MELD score on 
post-transplant day 5 to predict 90-day graft loss was 18.5 (area under the curve 0.8, 95% 
CI: 0.7-0.8) (Fig. S2). 
 
Comparison of different EAD definitions 
We evaluated the risk of EAD occurrence according to three different definitions: 
a) Total bilirubin ≥10 mg/dL or INR ≥1.6 on postoperative day 7 or AST or ALT >2000 IU/L 
within the first 7 days. 
328 out of 603 (54.4%) patients satisfied this definition. All the six patients who lost their 
graft within day 7 satisfied the criterion of conspicuously raised transaminase. 
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b) Peak total bilirubin >10 mg/dL on postoperative days 2 to 7. 
308 out of 601 patients (51.2%) satisfied this definition. The four patients who lost their 
graft between days 4 and 7 also satisfied this definition. 
c) MELD ≥19 on post-transplant day 5. 
314 out of 599 (52.4%) patients satisfied this definition. The 2 patients who lost their 
graft on days 5 and 7 showed on day 5 a MELD score of 41 and 32, respectively. 
Of the three definitions, a MELD score ≥19 on day 5 after surgery showed the highest 
positive likelihood ratio (1.9) and the lowest negative likelihood ratio (0.1) to predict 90-day 
graft loss (Table 2). This EAD definition satisfied the first study objective and was used for 
subsequent analyses. 
 
Ninety-day graft and patient survival 
Thirty-five out of 603 (5.8%) patients lost their graft within 90 days after surgery due to 
graft complications (6 primary non function, 12 delayed non function, 2 hepatic artery 
thrombosis, 1 biliary complication, 1 acute rejection, 1 hepatic veno-occlusive disease), 
infection and multi organ failure (9 patients), HCV recurrence (2 patients), cardiac failure (1 
patient). Twenty patients (3.3%) with graft complications underwent re-LT, while 18 
patients (3.0%) died within 90 days of LT (Table 1). 
The occurrence of EAD significantly worsened the 90-day graft (90.8% vs. 99.3%,  
p<0.001) and patient (94.9% vs. 99.6%, p<0.001) survival rates (Fig. 1A and 1B). 
 
Risk factors for EAD 
Table 3 shows the association of clinical factors with EAD at univariate analysis.  
The rates of HCC and of HCV RNA negativity were significantly higher in the non-EAD 
group. On the other hand, MELD at LT, donor age x recipient MELD, donor risk index, cold 
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ischemia time and in-hospital stay were significantly reduced in the non-EAD group 
compared with the EAD one.  
To account for the changes in transplant care and performance which occurred over time, 
we compared the first (Nov 2002 – Mar 2009; n=300) with the second (Apr 2009 – Jun 
2016; n=299) half of patients enrolled in the study. EAD rate decreased from 61.3% in the 
earlier era to 43.5% in the more recent one (p<0.001). The latter era was characterized by 
a significant increased donor age and incidence of graft macrovesicular steatosis ≥30%, 
whilst the cold ischemia time duration and the proportion of hepatitis B core antibody 
positive grafts were lower and the rates of HCC and HCV RNA negative patients at LT 
were higher (Table S2). 
Table 4 depicts as HCV RNA negative patients compared with positive ones, showing a 
significantly higher rate of HCC, and a lower MELD score at LT. Median donor age and the 
rate of graft macrovesicular steatosis ≥30% were significantly higher in the negative group. 
Table 5 summarizes the results of the multivariate logistic regression performed on a set 
of recipient and donor features available at LT. All variables significantly associated with 
EAD at univariate analysis, were included, except for donor risk index which was replaced 
by donor age due to its well-known detrimental effect on LT outcomes in HCV positive 
recipients. We forced into the analysis also graft macrovesicular steatosis ≥30%, because 
we observed that four such livers were lost within day 4 post-transplant and were 
consequently missed by EAD defined as MELD ≥19 on day 5. 
A MELD score at LT >25 (OR=7.4), graft macrovesicular steatosis ≥30% (OR=6.7), a 
MELD score al LT between 15 and 25 (OR=3.2), HCV RNA positivity at LT (OR=2.7), 
donor age >70 years (OR=2.0), earlier transplant era (OR=1.8) and a cold ischemia time 
≥8 hours (OR=1.8) resulted as independent predictors of EAD. 
HCV RNA was an independent predictor of EAD also when the analysis was restricted to 
the more recent era (OR=2.7) (Table S3).  
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In the 193 patients who received a liver graft older than 70 years, EAD occurred in 61.5% 
(99/161) of HCV RNA positive as opposed to 21.9% (7/32) of HCV RNA negative 
recipients (p<0.001). 
 
DISCUSSION 
We studied a series of more than six hundred HCV-positive recipients consecutively 
transplanted from HCV-negative donors and found a significant impact of HCV RNA status 
at transplant on the incidence of early graft dysfunction. 
The advent of DAAs has revolutionized anti-HCV therapy, especially in the LT setting. 
Indeed, their remarkably good safety profile currently allows to treat patients either before 
or after LT, so that a heated controversy on the optimal timing for treatment is going on (3-
5). According to a recent decision analytical simulation model of 10,000 patients with Child 
B and C cirrhosis, treatment before LT seems to be the most cost-effective strategy for 
patients with decompensated cirrhosis and MELD >13 (18). Furthermore, a European 
multicenter study showed that DAAs may lead to a remarkable clinical improvement and 
organ salvage because 19.2% of the patients treated while on the transplant waiting list 
were delisted at 60 weeks from the beginning of antiviral therapy (6). Finally, prevention of 
graft HCV infection simplifies post-LT patient management. Nevertheless, lower rates of 
virological response in decompensated cirrhotics compared with post-LT recipients and 
unpredictable waiting time on the LT list can lead clinicians to prefer the post-LT approach, 
especially for patients with MELD >18-20, where data on the efficacy of the new 
treatments are scanty (19-23). Furthermore, mindful that HCV RNA levels fall sharply at 
LT, after removal of the liver, the results of a very short pre-emptive antiviral strategy have 
been recently published. Sixteen patients received sofosbuvir plus ledipasvir one day 
before and 4 weeks after LT: 33% of the patients showed an HCV RNA inferior to 15 
IU/mL on day seven after LT and the rate of SVR12 was 88% (24).  
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At present, to meet the growing LT demand and the persistent organ shortage, the 
transplant community is using more and more suboptimal grafts, which are associated with 
an increased risk of initial poor function and early graft failure. For this reason, in this 
exciting era of powerful DAAs, we focused on the HCV-positive recipients and investigated 
whether avoiding HCV re-infection at the time of reperfusion could have beneficial effects 
on the early functional recovery of the graft. With this aim we studied EAD, a well-known 
predictor of early graft loss in the transplant population (11-13). 
We compared three different, previously established, EAD definitions: 1) Olthoff et al, 
which considers acute hepatocyte injury (high level of transaminases during the first 
week), cholestasis and coagulopathy at one week from LT; 2) Deschênes et al, which is 
based on bilirubin level during days 2 to 7 after LT; 3) Wagener et al, which uses the 
MELD score on day 5 post-LT, expressing graft function and postoperative complications 
such as infections often associated to renal failure.  
More than half of our HCV patients experienced EAD by every definition used, against a 
significantly lower rate in our non-HCV patients (around 45%, unpublished data). Exclusive 
HCV etiology and high donor risk index in this study cohort can explain an higher rate of 
EAD than that reported in other cohorts (which enrolled patients with end-stage liver 
disease of any etiology); nevertheless our patients showed good 90-day graft and patient 
survival rates (11,13,14). Similarly to what reported in Wagener’s paper (13) on 572 LT 
recipients (half of them being infected by HCV), we found that a MELD score ≥19 on day 5 
post-transplant allowed the best prediction of 90-day graft loss. Nearly 10% of EAD 
patients in our cohort and 17% in the American one lost their graft within 90 days of 
transplantation, against 0.7% and 2%, respectively, of non-EAD patients.  
Looking at predictors of EAD in our cohort, MELD score at LT, moderate/severe 
macrovesicular steatosis and advanced donor age exerted a negative impact, as expected. 
In addition, we confirmed a protective effect of a cold ischemia time shorter than 8 hours, an 
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expedient increasingly adopted by the surgical teams in the more recent years in response 
to an older donor age. Yet, the most intriguing finding of our study was the significantly and 
substantially reduced odds ratio for EAD in patients who were HCV RNA negative at LT; this 
finding was confirmed also when the analysis was restricted to the recent era. Notably, HCV 
RNA negative patients, compared with positive ones, showed a significantly higher rate of 
HCC, and as a consequence, a lower MELD score at LT; on the other hand median donor 
age and the rate of graft macrovesicular steatosis ≥30% were significantly higher in the 
negative group.  
Ischemia/reperfusion injury is recognized as the main culprit of initial poor graft function; it 
causes the infiltration of polymorphonuclear and T cells, activation of endothelial and 
Kupffer cells and formation of reactive oxygen species, all leading to hepatocyte injury 
through inflammation and cytotoxicity (25). Garcia-Retortillo et al (26) published 15 years 
ago a detailed study on early post-LT HCV kinetics. They showed in 20 patients that HCV 
RNA circulating levels decrease not only during the anhepatic phase, but also during the 
first 12 to 24 hours, presumably as a consequence of an uptake of the virus by the 
hepatocytes and/or the hepatic reticuloendothelial system; furthermore 12 of the 13 
patients who were on steroid immunosuppression experienced a persistent increase in 
HCV RNA in the first week. Likewise, Fukumoto et al (27) showed in 8 of 9 patients who 
received steroids, azathioprine and calcineurin-inhibitor, that HCV RNA levels increased 
after the second postoperative day, probably as expression of active viral synthesis, the 
immunosuppression regimen being the most important determinant of early viral kinetics 
(28).  
Even if sequential histological evaluations were not available in the first days after LT in 
our patients, we can speculate that the uptake and replication of the virus in the 
hepatocytes immediately after LT, could interfere with the physiological process of 
regeneration and functional recovery that normally follows ischemia-reperfusion injury.  
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Lastly, it should be noted that the very low EAD incidence that we recorded in HCV RNA 
negative recipients of grafts older than 70 years provides a new argument against the 
previously recommended judicious use of advanced age donors in HCV recipients (29). In 
this fashion, pre or peri-LT viral eradication could not only improve early LT outcomes but 
also increase LT opportunities for HCV-positive candidates, especially in countries mostly 
relying on elderly donors. 
Although more data on the safety and efficacy of DAAs in severely decompensated 
patients are eagerly awaited, our findings evidence a so far unrecognized benefit of 
preventing graft re-infection, thus giving new importance to the transplant hepatologists’ 
attempt at achieving HCV RNA negativization before transplant even in very sick patients. 
We acknowledge that this retrospective single-center study is limited by the long time 
needed to recruit an adequate number of patients and the possible effects of changes in 
transplant care and performance occurring over time. For this reason, we stratified our 
data for the transplant era, comparing the first with the second half of the study period 
when the EAD rate was significantly reduced despite a worse donor risk profile. In a 
multivariate analysis, as expected, the earlier transplant era emerged as an independent 
predictor of EAD, but this did not invalidate the significant role of the recipient HCV RNA 
positivity as an EAD risk factor. 
In conclusion, HCV-positive recipients presenting a MELD score ≥19 on day 5 post-LT are 
at increased risk of graft loss within 90 days of transplantation. Our data suggest that 
negativization of viremia by pre-LT antiviral therapy not only prevents graft infection at 
reperfusion, but also reduces EAD incidence. This therapeutic strategy  should be further 
investigated for its potential to improve early survival, especially in high MELD  patients 
and in recipients of grafts with suboptimal quality due to macrosteatosis or advanced 
donor age. 
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FIGURE LEGEND 
 
Figure 1. Ninety-day graft (A) and patient (B) survival in EAD (n=314) vs non-EAD 
(n=285) patients. EAD defined as MELD ≥19 on day 5 post-transplant. EAD, early 
allograft dysfunction; MELD, Model for End-stage Liver Disease. 
 
 
  
17 
 
REFERENCES 
 
1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 
2011;17:107-115.  
2. Terrault NA. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin 
Gastroenterol 2012;26:531-548.  
3. European Association for the Study of the Liver. EASL recommendations on 
treatment of hepatitis C 2016. J Hepatol 2017;66:153-194. 
4. Bunchorntavakul C and Reddy KR. Treat chronic hepatitis C virus infection in 
decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum 
in the era of effective and well-tolerated therapy. J Viral Hepat 2016;23:408-418. 
5. Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, et al. Optimal timing 
of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology 
2016, doi:10.1002/hep.28926 [Epub ahead of print]. 
6. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, 
et al. Delisting of liver transplant candidate with chronic hepatitis C after viral 
eradication: a European study. J Hepatol 2016;65:524-531. 
7. Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver 
transplantation phase: the sooner, the better. Gastroenterology 2015;148:13-16. 
8. Martini S, Sacco M, Strona S, Arese D, Tandoi F, Dell Olio D, et al. Impact of viral 
eradication with sofosbuvir-based therapy on the outcome of post-transplant 
hepatitis C with severe fibrosis. Liver Int 2017;37(1):62-70. 
9. Briceño J, Ciria R, de la Mata M, Rufián S, López-Cillero P. Prediction of graft 
dysfunction based on extended criteria donors in the model for end-stage liver 
disease era. Transplantation 2010;90:530-539. 
 
18 
 
10. Wadei HM, Lee DD, Croome KP, Mai ML, Golan E, Brotman R, et al. Early allograft 
dysfunction after liver transplantation is associated with short- and long-term kidney 
function impairment. Am J Transplant 2016;16:850-859. 
11. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. 
Validation of a current definition of early allograft dysfunction in liver transplant 
recipients and analysis of risk factors. Liver Transpl 2010;16:943-949. 
12. Deschênes M, Belle SH, Krom RA, Zetterman RK, Lake JR. Early allograft 
dysfunction after liver transplantation: a definition and predictors of outcome. 
National Institute of Diabetes and Digestive and Kidney Diseases Liver 
Transplantation Database. Transplantation 1998;66:302-310. 
13. Wagener G, Raffel B, Young AT, Minhaz M, Emond J. Predicting early allograft 
failure and mortality after liver transplantation: the role of the postoperative Model 
for End-stage Liver Disease score. Liver Transpl 2013;19:534-542. 
14. Hoyer DP, Paul A, Gallinat A, Molmenti EP, Reinhardt R, Minor T, et al. Donor 
information based prediction of early allograft dysfunction and outcome of liver 
transplantation. Liver Int 2015;35:156-163. 
15. Oweira H, Lahdou I, Daniel V, Opelz G, Schmidt J, Zidan A, et al. Early post-
operative acute phase response in patients with early graft dysfunction is predictive 
of 6-month and 12-month mortality in liver transplant recipients. Human 
Immunology 2016;77:952-960. 
16. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, et al. 
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver 
transplantation: an open-label study. Gastroenterology 2015;148:100-107. 
17. Donato MF, Morelli C, Romagnoli R, Invernizzi F, Mazzarelli C, Iemmolo RM, et al. 
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre to 
19 
 
post liver transplant: a real life strategy. Liver Int 2016, doi: 10.1111/liv.13322. [Epub 
ahead of print]. 
18. Tapper EB, Hughes MS, Buti M, Dufour J-F, Flamm S, Firdoos S, et al. The optimal 
timing of hepatitis C therapy in transplant eligible patients with Child B and C 
cirrhosis: a cost-effectiveness analysis. Transplantation 2016, 
10.1097/TP.0000000000001400. [Epub ahead of print]. 
19. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. 
Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients 
with advanced liver disease. Gastroenterology 2015;149:649-659. 
20. Manns M, Samuel D, Gane JE, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir 
and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus 
infection and advanced liver disease: a multicentre, open-label, randomised, phase 
2 trial. Lancet Infect Dis 2016;16:685-697. 
21. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. 
Outcomes after successful direct-acting antiviral therapy for patients with chronic 
hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-747. 
22. Foster FR, Irving WL, Cheung MC, Waljer AJ, Hudson BE, Verma S, et al. Impact 
of direct acting antiviral therapy in patients with chronic hepatitis C and 
decompensated cirrhosis. J Hepatol 2016;64:1224-1231. 
23. Vinaixa C, Coilly A, Belli LS, Mix H, Duvoux C, Berenguer M. Safety and efficacy of 
interferon-free antiviral treatment in hepatitis C patients with MELD score 20 and 
over [abstract]. Hepatology 2016;64(Suppl):986A. 
24. Levitsky J, Verna EC, O’Leary JG; Bzowej NH, Moonka DK, Hyland RH, et al. 
Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients. N Engl J 
Med. 2016;375(21):2106-8. 
 
20 
 
25. Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion 
injury: effects on the liver sinusoidal milieu. J Hepatol 2013;59:1094-1106. 
26. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. 
Hepatitis C virus kinetics during and immediately after liver transplantation. 
Hepatology 2002;35:680-687. 
27. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, et al. Viral 
dynamics of hepatitis C early after orthotopic liver transplantation: evidence for 
rapid turnover of serum virions. Hepatology 1996;24:1351-1354. 
28. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of 
hepatitis C virus recurrence. Liver Transpl 2003;9:S58-S62. 
29. European Association for the Study of the Liver. EASL clinical practice guidelines: 
liver transplantation. J Hepatol 2016;64:433-485.  
 
  
21 
 
Table 1. Recipient and donor characteristics. 
 Study population (n=603) 
Recipient features  
Age (years) 55.8 [50.6-61.2] 
Male gender 487 (80.8%) 
Body Mass Index (Kg/m2) 25 [23-27] 
Hepatocellular carcinoma 322 (53.4%) 
MELD at LT 15 [11-19] 
HCV RNA negative at LT 77 (12.8%) 
Donor features  
Age (years) 63.0 [50.7-72.3] 
Male gender 341 (56.6%) 
Body Mass Index (Kg/m2) 25 [23-28] 
Body Mass Index ≥30 Kg/m2 71 (11.8%) 
Cause of brain death  
Cerebrovascular 
Trauma 
Anoxia 
Other 
436 (72.3%) 
106 (17.6%) 
50 (8.3%) 
11 (1.8%) 
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HBcAb positivity 69 (11.4%) 
Donor Risk Index 1.8 [1.5-2.1] 
Macrovesicular steatosis ≥30%* 18 (3.0%) 
Donor-Recipient match 
Donor age x Recipient MELD   901 [625-1219] 
Transplant times 
Cold ischemia time (min) 
Cold Ischemia time ≥8 hours 
Warm ischemia time (min) 
 
469 [401-539] 
280 (46.4%) 
23 [20-28] 
90-day outcomes  
Graft loss 35 (5.8%) 
Retransplantation 20 (3.3%) 
Patient death 18 (3.0%) 
Numerical variables: median [Q1-Q3]; categorical variables: numbers (prevalence, %). 
*3 missing. 
Abbreviations: HBcAb, hepatitis B core antibody; LT, liver transplantation; MELD, Model 
for End-stage Liver Disease. 
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Table 2. Comparison of the different EAD definitions. 
 Olthoff# 
Bilirubin 
>10mg/dL  
on days 2 to 7 
MELD ≥19  
on day 5 
EAD rate 328/603 (54.4%) 308/601^ (51.2%) 314/599* (52.4%) 
Graft loss 90-day, EAD vs no 
EAD 
9.8% vs 1.1% 8.4% vs 2.4% 9.2% vs 0.7% 
Sensitivity (95% CI) 0.9 (0.8-1.0) 0.8 (0.6-0.9) 0.9 (0.8-1.0) 
Specificity (95% CI) 0.5 (0.4-0.5) 0.5 (0.5-0.5) 0.5 (0.5-0.5) 
Positive predictive value (95%CI) 0.01 (0.002-0.03) 0.02 (0.01-0.05) 0.01 (0.001-0.03) 
Negative predictive value(95%CI) 0.9 (1.0-0.9) 0.9 (1.0-0.9) 0.9 (0.9-0.9) 
Positive likelihood ratio 1.8 1.6 1.9 
Negative likelihood ratio 0.2 0.4 0.1 
#Total bilirubin ≥10 mg/dL or INR ≥1.6 on postoperative day 7 or AST or ALT >2000 IU/L within the 
first 7 days after transplant. 
^2 patients lost their graft on day 1 after transplant. 
*4 patients lost their graft within day 4 after transplant. 
Abbreviations: CI, confidence interval; EAD, early allograft dysfunction; MELD, Model for End-stage 
Liver Disease. 
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Table 3. Differences between EAD and non-EAD recipients at univariate analysis. 
 
EAD defined as MELD ≥19 on day 5 post-transplant. 
 
 
EAD 
(n=314) 
No EAD 
(n=285) 
p 
Recipient features    
Age (years) 55.4 [49.5-60.7] 56.0 [50.9-61.4] 0.23 
Male gender 259 (82.5%) 224 (78.6%) 0.23 
Body Mass Index (Kg/m2) 25 [23-27] 25 [23-27] 0.24 
Hepatocellular carcinoma 136 (43.3%) 183 (64.2%) <0.001 
MELD at LT 
<15 
15-25 
>25 
17 [13-22] 
102 (32.5%) 
156 (49.7%) 
56 (17.8%) 
13 [9-17] 
179 (62.8%) 
89 (31.2%) 
17 (6.0%) 
<0.001 
 
<0.001 
 
HCV RNA negative at LT 19 (6.1%) 57 (20.0%) <0.001 
Donor features    
Age (years) 
<50 
50-70 
>70 
63.6 [51.9-72.8] 
67 (21.3%) 
141 (44.9%) 
106 (33.8%) 
62.2 [49.3-71.8] 
74 (26.0%) 
124 (43.5%) 
87 (30.5%) 
0.40 
 
0.39 
 
Male gender 172 (54.8%) 165 (57.9%) 0.44 
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Cause of brain death    
Cerebrovascular 
Trauma 
Anoxia 
Other 
235 (74.8%) 
56 (17.8%) 
18 (5.8%) 
5 (1.6%) 
198 (69.5%) 
50 (17.5%) 
32 (11.2%) 
5 (1.8%) 
0.11 
Body Mass Index (Kg/m2) 25 [23-28] 25 [23-29] 0.30 
Body Mass Index ≥30 Kg/m2 39 (12.4%) 30 (10.5%) 0.47 
Donor Risk Index 1.8 [1.6-2.1] 1.8 [1.5-2.0] 0.003 
HBcAb positive 41 (13.0%) 27 (9.5%) 0.17 
Macrovesicular steatosis ≥30% 10 (3.2%)* 4 (1.4%)# 0.15 
Donor-Recipient match    
Donor age x Recipient MELD   1033 [749-1400] 730 [518-1018] <0.001 
Transplant times    
Cold ischemia time (min) 492 [420-562] 449 [383-512] <0.001 
Cold Ischemia Time ≥8 hours 174 (55.4%) 105 (36.8%) <0.001 
Warm ischemia time (min) 23 [20-28] 23 [20-27] 0.78 
Outcomes 
Hospitalization (days) 
 
16 [12-26] 
 
11 [9-16] 
 
<0.001 
Intensive care unit (days) 4 [2-8] 3 [2-4] <0.001 
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Graft loss within 90 days 29 (9.2%) 2 (0.7%) <0.001 
Re-LT within 90 days 15 (4.8%) 1 (0.4%) <0.001 
Patient death within 90 days 16 (5.1%) 1 (0.4%) <0.001 
Liver transplant era    
Nov 2002-Mar 2009 (n=300)                                 
Apr 2009-Jun 2016 (n=299) 
184 (61.3%) 
130 (43.5%) 
116 (38.7%) 
169 (56.5%) 
<0.001 
Numerical variables: median [Q1-Q3]; categorical variables: numbers (prevalence, %). 
*2 and #1 missing.  
Abbreviations: EAD, early allograft dysfunction; HBcAb, hepatitis B core antibody; LT, liver 
transplantation; MELD, Model for End-stage Liver Disease. 
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Table 4. Recipient and donor characteristics according to HCV RNA status at liver 
transplant. 
 
HCV RNA Positive 
(n=523) 
HCV RNA Negative 
(n=76) 
p 
Recipient features    
Hepatocellular carcinoma 269 (51.4%) 50 (65.8%) 0.02 
MELD at LT 
<15 
15-25 
>25 
15 [11-20] 
231 (44.2%) 
225 (43.0%) 
67 (12.8%) 
12 [8-17] 
50 (65.8%) 
20 (26.3%) 
6 (7.9%) 
<0.001 
 
0.002 
 
Era 
1 Nov 2002-Mar 2009 
2 Apr 2009-Jun 2016 
 
293 (56.0%) 
230 (44.0%) 
 
6 (7.9%) 
70 (92.1%) 
 
<0.001 
Donor features    
Age (years) 
<50 
50-70 
>70 
62.7 [50.4-71.8] 
127 (24.3%) 
233 (44.6%) 
163 (31.1%) 
66.4 [52.8-76.2] 
14 (18.4%) 
30 (39.5%) 
32 (42.1%) 
0.03 
 
0.15 
 
Donor Risk Index 1.8 [1.5-2.1] 1.9 [1.6-2.1] 0.45 
HBcAb positivity 60 (11.5%) 8 (10.5%) 0.81 
Macrovesicular steatosis ≥30% 9 (1.7%)* 5 (6.6%) 0.01 
Donor-Recipient match    
Donor age x Recipient MELD 931 [638-1252] 769 [544-1010] 0.01 
D-MELD >1750 37 (7.1%) 4 (5.3%) 0.56 
Transplant features    
Cold Ischemia Time (min) 478 [406-549] 429 [371-482] <0.001 
Cold Ischemia Time ≥8 hours 259 (49.5%) 20 (26.3%) <0.001 
Early allograft dysfunction 
(MELD ≥19 Day 5 post-LT) 
296 (56.6%) 19 (25.0%) <0.001 
Graft loss within 90 days 27 (5.2%) 4 (5.3%) 0.97 
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Re-LT within 90 days 13 (2.5%) 3 (3.9%) 0.46 
Patient death within 90 days 14 (2.7%) 3 (3.9%) 0.53 
Numerical variables: median [Q1-Q3]; categorical variables: number (prevalence, %) 
*3 missing 
Abbreviations: HBcAb, hepatitis B core positive antibody; LT, liver transplantation; MELD, model 
for end-stage liver disease. 
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Table 5. EAD predictors at multivariate logistic regression. EAD defined as MELD ≥19 
on day 5 post-transplant. 
Risk factor Odds Ratio 95% CI p 
MELD score at LT >25* 7.4 4.0-14.3 <0.001 
MELD score at LT 15-25* 3.2 2.2-4.8 <0.001 
HCV RNA positive at LT^ 2.7 1.5-5.1 0.002 
Donor age >70 years 2.0 1.2-3.3 0.01 
Macrovesicular steatosis ≥30% 6.7 1.9-29.1 0.01 
Cold ischemia time ≥8 hours 1.8 1.2-2.5 0.003 
Earlier transplant era 1.8 1.2-2.7 0.003 
*MELD score <15 as reference. 
^Donor age < 50 years as reference. 
Abbreviations: CI, confidence interval; EAD, early allograft dysfunction; LT, liver transplantation; 
MELD, Model for End-stage Liver Disease. 
 
 
 
